IPP Bureau
Rafa Laboratories lands $186 million BARDA contract to develop life-saving trauma drug
By IPP Bureau - November 23, 2025
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients
By IPP Bureau - November 23, 2025
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
AstraZeneca to invest $2 billion in Maryland manufacturing expansion
By IPP Bureau - November 22, 2025
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
Roche wins EU green light for one-minute injection cancer therapy
By IPP Bureau - November 22, 2025
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer
By IPP Bureau - November 21, 2025
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension
By IPP Bureau - November 21, 2025
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
India’s Diabetes Crisis: Awareness and monitoring gaps threaten millions
By IPP Bureau - November 21, 2025
According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients
By IPP Bureau - November 21, 2025
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
BPL Medical Technologies brings next-gen Korean ultrasound to India
By IPP Bureau - November 21, 2025
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
Healthium Medtech to invest Rs. 150 crore in new Sri City facility, create 400 jobs
By IPP Bureau - November 21, 2025
Merck’s two-drug HIV regimen hits phase 3 success
By IPP Bureau - November 21, 2025
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment
By IPP Bureau - November 21, 2025
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
GSK and Fleming Initiative launch bold new fight against antimicrobial resistance
By IPP Bureau - November 21, 2025
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
GSK teams up with LTZ Therapeutics to launch next-generation cancer therapies
By IPP Bureau - November 21, 2025
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
Merck KGaA fires up new supercomputer to turbocharge scientific breakthroughs
By IPP Bureau - November 21, 2025
Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure
